Trius receives $5m milestone payment from Bayer
Trius Therapeutics has received a $5m milestone payment from Bayer Healthcare for the achievement of all efficacy and safety objectives in the TR701-112 Phase III pivotal study.
The Phase III pivotal study of TR701-112 is the first of two pivotal Phase II trials designed to support the filing of a NDA with the FDA as well as MAA with the EMA.
The 112 study tested the oral dosage form of tedizolid phosphate versus the comparator linezolid (Zyvox) in patients with acute bacterial skin and skin structure infections (ABSSSI).
The second Phase 3 trial of tedizolid phosphate in ABSSSI, designated TR701-113, for its intravenous (IV) to oral transition therapy was initiated by the company in September 2011.
The company expects to report top-line data of the study in early 2013.
The 113 study is the first clinical trial conducted in collaboration with Bayer HealthCare and will recruit patients in North and South America, Europe, Australia, New Zealand, and South Africa.
Related Insight
Suppliers Directory
Rhenovia Pharma - Predictive CNS Drug Discovery & Development by Biosimulation
Using its unique biosimulation platform Rhenovia Pharma offers services and partnerships for pharmacological profiling, target identification and validation, search for synergistic drug combinations, risk assessment for safety and toxicity of drug candidates in the nervous system.
Contract Research & Services > Contract Research > Suppliers
Medical Research Network - Clinical Trial Support Organisation
The Medical Research Network (MRN) is a unique clinical trial support organisation (CTSO). The MRN has been involved in the conduct of over 50 clinical trials across a wide range of therapeutic areas, in particular oncology and rheumatology.
Contract Research & Services > Contract Research > Suppliers
Kinapse Life Science Consulting and Outsourcing Services
Founded in 2005, Kinapse provides consulting and outsourcing services to the global life sciences industries. Our clients include many of the world’s leading pharmaceutical, biotechnology, medical device and specialty pharmaceutical companies, government organisations and life sciences service providers.
Contract Research & Services > Contract Research > Suppliers
Hudson Robotics - Lab Automation Solutions.
We produce robots that allow users to easily turn microplate readers into automated screening systems. We have microplate movement and storage systems, as well as liquid handling solutions. We also offer complete workcells for biological research and drug discovery, in which our products are integrated with third party equipment to solve complex laboratory protocols.
Contract Research & Services > Contract Research > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Research Intelligence
Spectral Unmixing for Hyperspectral Images of Breast Cancer Preparations
Published by Carinthian Tech Research (CTR)
Contract Research & Services > Contract Research > White Papers
ILS Client List
Published by Investigator Location Services
Contract Research & Services > Contract Research > White Papers
Clinical Pharmacodynamics Services
Published by FOCUS Clinical Drug Development
Contract Research & Services > Contract Research > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.